BACKGROUND Surgical site infections (SSI) remain a major cause of morbidity after hepatectomy for hepatocellular carcinoma (HCC).AIM To identify the risk factors associated with SSI,and develop a nomogram to predict S...BACKGROUND Surgical site infections (SSI) remain a major cause of morbidity after hepatectomy for hepatocellular carcinoma (HCC).AIM To identify the risk factors associated with SSI,and develop a nomogram to predict SSI among patients undergoing hepatectomy.METHODS We retrospectively reviewed the data of patients diagnosed with HCC undergoing hepatectomy at two academic institutions in China,and evaluated the occurrence of SSI.Independent risk factors for SSI were identified using univariate and multivariate analyses.Based on these independent risk factors,a nomogram was established using the data of patients in the first institution,and was validated using data from an external independent cohort from the second institution.RESULTS The nomogram was established using data from 309 patients,whereas the validation cohort used data from 331 patients.The operation duration,serum albumin level,repeat hepatectomy,and ASA score were identified as independent risk factors.The concordance index (C-index) of the nomogram for SSI prediction in the training cohort was 0.86;this nomogram also performed well in the external validation cohort,with a C-index of 0.84.Accordingly,we stratified patients into three groups,with a distinct risk range based on the nomogram prediction,to guide clinical practice.CONCLUSION Our novel nomogram offers good preoperative prediction for SSIs in patients undergoing hepatectomy.展开更多
Although targeted therapies and immunotherapies have been effective againstseveral malignancies, the respective monotherapies are limited by low and/orshort-term responses. Specific inhibitors of oncogenic signaling p...Although targeted therapies and immunotherapies have been effective againstseveral malignancies, the respective monotherapies are limited by low and/orshort-term responses. Specific inhibitors of oncogenic signaling pathways andtumor-associated angiogenesis can activate the anti-tumor immune responses byincreasing tumor antigen presentation or intratumor T cell infiltration. Additionalinsights into the effects and mechanisms of targeted therapies on the induction ofanti-tumor immunity will facilitate development of rational and effective combinationstrategies that synergize rapid tumor regression and durable response. Inthis review, we have summarized the recent combinations of targeted therapiesand immunotherapies, along with the associated clinical challenges.展开更多
文摘BACKGROUND Surgical site infections (SSI) remain a major cause of morbidity after hepatectomy for hepatocellular carcinoma (HCC).AIM To identify the risk factors associated with SSI,and develop a nomogram to predict SSI among patients undergoing hepatectomy.METHODS We retrospectively reviewed the data of patients diagnosed with HCC undergoing hepatectomy at two academic institutions in China,and evaluated the occurrence of SSI.Independent risk factors for SSI were identified using univariate and multivariate analyses.Based on these independent risk factors,a nomogram was established using the data of patients in the first institution,and was validated using data from an external independent cohort from the second institution.RESULTS The nomogram was established using data from 309 patients,whereas the validation cohort used data from 331 patients.The operation duration,serum albumin level,repeat hepatectomy,and ASA score were identified as independent risk factors.The concordance index (C-index) of the nomogram for SSI prediction in the training cohort was 0.86;this nomogram also performed well in the external validation cohort,with a C-index of 0.84.Accordingly,we stratified patients into three groups,with a distinct risk range based on the nomogram prediction,to guide clinical practice.CONCLUSION Our novel nomogram offers good preoperative prediction for SSIs in patients undergoing hepatectomy.
基金The National Key Research and Development Program of China,No.2019YFC1316000the National High Technology Research and Development Program of China,No.2015AA020405+1 种基金the National Natural Science Foundation of China,No.81672337China Postdoctoral Science Foundation,No.2020M671761.
文摘Although targeted therapies and immunotherapies have been effective againstseveral malignancies, the respective monotherapies are limited by low and/orshort-term responses. Specific inhibitors of oncogenic signaling pathways andtumor-associated angiogenesis can activate the anti-tumor immune responses byincreasing tumor antigen presentation or intratumor T cell infiltration. Additionalinsights into the effects and mechanisms of targeted therapies on the induction ofanti-tumor immunity will facilitate development of rational and effective combinationstrategies that synergize rapid tumor regression and durable response. Inthis review, we have summarized the recent combinations of targeted therapiesand immunotherapies, along with the associated clinical challenges.
